Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
© Brose et al; licensee BioMed Central Ltd. 2011
Received: 23 March 2011
Accepted: 11 August 2011
Published: 11 August 2011
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|23 Mar 2011||Submitted||Original manuscript|
|Resubmission - Version 2|
|Submitted||Manuscript version 2|
|29 Mar 2011||Author responded||Author comments - Martin Schlumberger|
|Resubmission - Version 3|
|29 Mar 2011||Submitted||Manuscript version 3|
|24 Jul 2011||Reviewed||Reviewer Report - Dirk Vordermark|
|9 Aug 2011||Author responded||Author comments - Martin Schlumberger|
|Resubmission - Version 4|
|9 Aug 2011||Submitted||Manuscript version 4|
|11 Aug 2011||Editorially accepted|
|11 Aug 2011||Article published||10.1186/1471-2407-11-349|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.